ICI 105552: RN given refers to Na salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 23689278 |
| MeSH ID | M0104354 |
| Synonym |
|---|
| i.c.i. 105552 |
| ici 105552 |
| 4-quinolineacetic acid, 1-((3,4-dichlorophenyl)methyl)-1,2-dihydro-3-methyl-2-oxo-, sodium salt |
| 1-((3,4-dichlorobenzyl)-3-methyl)-1,2-dihydro-2-oxoquinol-4-ylacetate |
| 2,4-cyclohexadien-1-one, 3-(acetyloxy)-6-((3,4-dichlorophenyl)methyl)-6-hydroxy-2-methyl- |
| ici105552 |
| 81420-31-7 |
| DTXSID80231097 |
| sodium;2-[1-[(3,4-dichlorophenyl)methyl]-3-methyl-2-oxoquinolin-4-yl]acetate |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with ICI 105552 affected neither glycaemia nor tissue glucose nor inositol concentrations yet reduced significantly the abnormal accumulations in diabetes of sorbitol in the lens (70% reduction), sciatic nerve (86%) and seminal vesicles with coagulating glands (S.V.C.G., 55%)." | ( Inhibition of aldose reductase in five tissues of the streptozotocin-diabetic rat. Heath, H; Poulsom, R, 1983) | 0.61 |
Sorbol pathway may be involved in the pathogenesis of retinopathy. In the retinas of controls, dosage with ICI 105552 reduced the concentration of sorbitol by 36% without other effects.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the retinas of controls, dosage with ICI 105552 reduced the concentration of sorbitol by 36% without other effects." | ( The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats. Earl, DC; Heath, H; Mirrlees, DJ; Poulsom, R, 1983) | 0.53 |
| "To test the possible involvement of the sorbitol pathway in the pathogenesis of retinopathy in long-term experimentally-diabetic rats, streptozotocin-diabetic and normal rats were dosed orally (50 mg/kg body weight daily) for up to 373 days with an aldose reductase inhibitor (ICI 105552) or a placebo." | ( The effects of long-term treatment of streptozotocin-diabetic rats with an aldose reductase inhibitor. Boot-Handford, RP; Heath, H; Poulsom, R, 1983) | 0.44 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (87.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||